LUẬN án TIẾN sĩ dược học FULL (CND và BC) tổng hợp hydroxyalkyl β cyclodextrin ứng dụng làm tá dược tăng độ tan trong bào chế thuốc

i BỘ GIÁO DỤC VÀ ĐÀO TẠO BỘ Y TẾ ĐẠI HỌC Y DƯỢC THÀNH PHỐ HỒ CHÍ MINH TỔNG HỢP HYDROXYALKYL-β-CYCLODEXTRIN ỨNG DỤNG LÀM TÁ DƯỢC TĂNG ĐỘ TAN TRONG BÀO CHẾ THUỐC Chuyên ngành: Công nghệ dược phẩm Mã số: 62730101 LUẬN ÁN TIẾN SĨ DƯỢC HỌC Người hướng dẫn khoa học: PGS.TS Đặng Văn Tịnh PGS.TS Huỳnh Văn Hóa TP Hồ Chí Minh ii LỜI CAM ĐOAN Tơi cam đoan cơng trình nghiên cứu Các số liệu, kết nêu luận án trung thực chƯa đƯợc cơng bố cơng trình khác MỤC LỤC Trang Trang phụ bìa Lời cam đoan MỤC LỤC iii DANH MỤC CÁC KÝ HIỆU, CÁC CHỮ VIẾT TẮT vi DANH MỤC CÁC BẢNG ix DANH MỤC CÁC HÌNH .xiii DANH MỤC CÁC BIỂU ĐỒ xiv DANH MỤC CÁC SƠ ĐỒ xvi ĐẶT VẤN ĐỀ CHƯƠNG TỔNG QUAN TÀI LIỆU 1.1 Tổng hợp 2-hydroxypropyl-β-cyclodextrin (HPβCD) 1.2 Tổng hợp 2-hydroxybutyl-β-cyclodextrin (HBβCD) 13 1.3 Tối Ưu hóa thơng số phản ứng tổng hợp 14 1.4 Phức thuốc-hydroxypropyl-β-cyclodextrin (thuốc-HPβCD) 15 1.5 Phức thuốc-hydroxybutyl-β-cyclodextrin (thuốc-HBβCD) 25 1.6 Các hoạt chất đƯợc ứng dụng để tạo phức với 2-hydroxypropyl-β-cyclodextrin 2-hydroxybutyl-β-cyclodextrin 26 CHƯƠNG - ĐỐI TƯỢNG VÀ PHƯƠNG PHÁP NGHIÊN CỨU 31 2.1 Đối tƯợng, hóa chất, dung mơi, ngun liệu, trang thiết bị 31 2.1.1 Đối tƯợng nghiên cứu 31 2.1.2 Hóa chất, dung mơi, ngun liệu, máy, thiết bị dùng cho tổng hợp, điều chế 31 2.1.3 Tối Ưu hóa qui trình tổng hợp xử lý thống kê với trợ giúp phần mềm: 33 2.2 PhƯơng pháp nghiên cứu 33 2.2.1 Tổng hợp 2-hydroxypropyl-β-cyclodextrin (HPβCD) 33 2.2.2 Tổng hợp 2-hydroxybutyl-β-cyclodextrin (HBβCD) 40 2.2.3 Điều chế phức rutin-hydroxypropyl-β-cyclodextrin (R-HPβCD) .42 2.2.4 Điều chế phức rutin-hydroxybutyl-β-cyclodextrin (R-HBβCD) .46 2.2.5 So sánh độ hòa tan, độ tan rutin phức R-HBβCD rutin phức R-HPβCD 47 2.2.6 Điều chế phức itraconazol-hydroxypropyl-β-cyclodextrin (ITZ-HPβCD) 47 2.2.7 Điều chế phức itraconazol-hydroxybutyl-β-cyclodextrin (ITZ-HBβCD) 49 2.2.8 So sánh độ hòa tan, độ tan itz phức ITZ-HBβCD itz phức ITZ-HPβCD 50 2.2.9 Điều chế phức meloxicam-hydroxypropyl-β-cyclodextrin (ME-HPβCD) 50 CHƯƠNG KẾT QUẢ NGHIÊN CỨU 53 3.1 Tổng hợp 2-hydroxypropyl-β-cyclodextrin (HPβCD) 53 3.2 Tổng hợp 2-hydroxybutyl-β-cyclodextrin (HBβCD) 65 3.3 Điều chế phức rutin-hydroxypropyl-β-cyclodextrin (R-HPβCD) 75 3.4 Điều chế phức rutin-hydroxybutyl-β-cyclodextrin (R-HBβCD) 82 3.5 So sánh độ hòa tan, độ tan rutin phức R-HBβCD rutin phức R-HPβCD 86 3.6 Điều chế phức itraconazol-hydroxypropyl-β-cyclodextrin (ITZ-HPβCD) 88 3.7 Điều chế phức itraconazol-hydroxybutyl-β-cyclodextrin (ITZ-HBβCD) .93 3.8 So sánh độ hòa tan, độ tan itz phức ITZ-HBβCD itz phức ITZ-HPβCD 98 3.9 Điều chế phức meloxicam-hydroxypropyl-β-cyclodextrin (ME-HPβCD) 100 CHƯƠNG BÀN LUẬN 106 4.1 Tổng hợp 2-hydroxypropyl-β-cyclodextrin 106 4.2 Tổng hợp 2-hydroxybutyl-β-cyclodextrin 120 4.3 Điều chế phức R-HPβCD 124 4.4 Điều chế phức R-HBβCD 150 4.5 So sánh độ hòa tan, độ tan rutin phức R-HBβCD rutin phức R-HPβCD 151 4.6 Điều chế phức ITZ-HPβCD 151 4.7 Điều chế phức ITZ-HBβCD 156 4.8 So sánh độ hòa tan, độ tan itz phức ITZ-HBβCD itz phức ITZ-HPβCD 132 4.9 Điều chế phức ME-HPβCD 132 KẾT LUẬN 161 KIẾN NGHỊ 162 DANH MỤC CÁC CƠNG TRÌNH NGHIÊN CỨU ĐÃ CÔNG BỐ TÀI LIỆU THAM KHẢO PHỤ LỤC DANH MỤC CÁC KÝ HIỆU, CÁC CHỮ VIẾT TẮT Ký hiệu, từ viết tắt Chữ đầy đủ nghĩa tiếng Việt AUC Area Under the Curve (Diện tích đường cong) BP British Pharmacopoeia (Dược điển Anh) CE Complexation Efficiency (Hiệu tạo phức) Cmax Nồng độ tối đa COSY Correlation Spectroscopy: (Phổ COSY) d Doublet (Mũi đôi) dd Doublet of doublets (Mũi đôi-đôi) DĐVN DƯợc điển Việt nam DEPT Distortionless Enhancement by Polarization Transfer (Phổ DEPT) dm Dung môi DMF Dimethylformamid DMSO Dimethylsulfoxyd DS Degree of Substitution (Độ thế) DSC Differential Scanning Calorimetry (Phân tích nhiệt vi sai) Eur Ph European Pharmacopoeia (Dược điển Châu Âu) HBβCD 2-hydroxybutyl-β-cyclodextrin HMBC Heteronuclear Multiple Bond Coherence (Phổ HMBC) HPLC High Performance Liquid Chromatography (Sắc ký lỏng hiệu cao) HPβCD 2-hydroxypropyl-β-cyclodextrin HSQC Heteronuclear Single Quantum Correlation (Phổ HSQC) IR Infrared (Hồng ngoại) Itz Itraconazol vii ITZ-HBβCD Phức itraconazol-hydroxybutyl-β-cyclodextrin ITZ-HPβCD Phức itraconazol-hydroxypropyl-β-cyclodextrin J Hằng số ghép K1:1 Hằng số cân (Hằng số bền phức chất) kDa Kilodalton (Đơn vị đo khối lượng phân tử) kl/tt Khối lƯợng/thể tích m Multiplet (Mũi đa) ME Meloxicam m/z Tỷ lệ khối lƯợng điện tích ion ME-HPβCD Phức MS Mass Spectroscopy (Phổ khối) ms Molar substitution (Mức độ thay phân tử) NMR Nuclear Magnetic Resonance (Cộng hưởng từ hạt nhân) NOESY Nuclear Overhauser Enhancement Spectroscopy (Phổ NOESY) pic Đỉnh, (Mũi) ppm Part per million (Phần triệu) R-HBβCD Phức rutin-hydroxybutyl-β-cyclodextrin R-HPβCD Phức rutin-hydroxypropyl-β-cyclodextrin ROESY Rotating-Frame Overhauser Enhancement Spectroscopy (Phổ meloxicam-hydroxypropyl-β-cyclodextrin ROESY) RSD Relative Standard Deviation (Độ lệch chuẩn tương đối) s Singlet (Mũi đơn) SD Standard Deviation (Độ lệch chuẩn) SEM Scanning Electron Microscope (Kính hiển vi điện tử quét) t Triplets (Mũi ba) TCCS Tiêu chuẩn sở TCNSX Tiêu chuẩn nhà sản xuất TLC Thin Layer Chromatography (Sắc ký lớp mỏng) Tmax Thời gian đạt nồng độ tối đa TT Thuốc Thử tt Thể tích USP-NF The United States Pharmacopoeia and The National Formulary (Dược điển Dược thư Hoa kỳ) UV Ultraviolet (Tử ngoại) X Giá trị trung bình βCD Beta Cyclodextrin DANH MỤC CÁC BẢNG Trang Bảng 2.1 Danh mục nguyên liệu hóa chất dùng cho tổng hợp 31 Bảng 2.2 Danh mục nguyên liệu dùng cho điều chế phức 31 Bảng 2.3 Danh mục hóa chất dùng cho phân tích, kiểm nghiệm 32 Bảng 2.4 Danh mục máy, thiết bị 32 Bảng 3.1 Ảnh hƯởng nồng độ NaOH đến hiệu suất DS phản ứng tổng hợp HPβCD 54 Bảng 3.2 So sánh phổ IR HPβCD tổng hợp HPβCD thƯơng mại 54 13 Bảng 3.3 So sánh độ dịch chuyển hóa học phổ H C-NMR HPβCD tổng hợp HPβCD thƯơng mại 55 Bảng 3.4 Ảnh hƯởng vận tốc khuấy đến hiệu suất DS phản ứng tổng hợp HPβCD 56 Bảng 3.5 Ảnh hƯởng nhiệt độ đến hiệu suất DS phản ứng tổng hợp HPβCD 56 Bảng 3.6 Ảnh hƯởng thời gian đến hiệu suất DS phản ứng tổng hợp HPβCD 57 Bảng 3.7 Mã hóa yếu tố biến thiên khảo sát qui trình tổng hợp HPβCD .58 Bảng 3.8 Bố trí thí nghiệm Box-Behnken mức kiểu bề mặt đáp ứng kết hiệu suất DS qui trình tổng hợp HPβCD .59 Bảng 3.9 Hiệu suất DS phản ứng tổng hợp HPβCD điều kiện tối Ưu 60 Bảng 3.10 Sản phẩm phản ứng tổng hợp HPβCD với tỷ lệ mol βCD : 1,2-propylen oxid khác 61 Bảng 3.11 Hiệu suất DS phản ứng tổng hợp HPβCD cỡ lô kg .62 Bảng 3.12 Kết kiểm nghiệm HPβCD tổng hợp 63 Bảng 3.13 Độ ổn định HPβCD tổng hợp 64 Bảng 3.14 Công thức (cho lô) tổng hợp HPβCD 64 Bảng 3.15 Ảnh hƯởng nồng độ NaOH đến hiệu suất DS phản ứng tổng hợp HBβCD 66 Bảng 3.16 Ảnh hƯởng vận tốc khuấy đến hiệu suất DS phản ứng tổng hợp HBβCD 67 Bảng 3.17 Ảnh hƯởng nhiệt độ đến hiệu suất DS phản ứng tổng hợp HBβCD 68 Bảng 3.18 Ảnh hƯởng thời gian đến hiệu suất DS phản ứng tổng hợp HBβCD 68 Bảng 3.19 Mã hóa yếu tố biến thiên khảo sát phản ứng tổng hợp HBβCD 69 Bảng 3.20 Bố trí thí nghiệm Box-Behnken mức kiểu bề mặt đáp ứng kết hiệu suất DS qui trình tổng hợp HBβCD 70 Bảng 3.21 Hiệu suất DS phản ứng tổng hợp HBβCD điều kiện tối Ưu 71 Bảng 3.22 Sản phẩm HBβCD với tỷ lệ mol βCD : 1,2-butylen oxid khác 72 Bảng 3.23 Hiệu suất DS phản ứng tổng hợp HBβCD cỡ lô kg .72 Bảng 3.24 Kết kiểm nghiệm HBβCD tổng hợp 73 Bảng 3.25 Độ ổn định HBβCD tổng hợp 74 Bảng 3.26 Công thức (cho lô) tổng hợp HBβCD 74 Bảng 3.27 TƯơng quan nồng độ độ hấp thụ phổ UV dung dịch rutin chuẩn 362,5 nm 75 Bảng 3.28 Độ xác quy trình định lƯợng rutin phức R-HPβCD 76 Bảng 3.29 Độ tan rutin dung dịch HPβCD nồng độ từ - 10 mmol 76 Bảng 3.30 Độ tan rutin phức R-HPβCD với tỷ lệ mol khác 77 Bảng 3.31 Độ hòa tan rutin rutin phức R-HPβCD điều chế phƯơng pháp nghiền Ướt đồng bay dung môi .79 Bảng 3.32 Độ tan rutin rutin phức R-HPβCD điều chế phƯơng pháp đồng bay dung môi 80 Bảng 3.33 Biện giải phổ IR rutin, HPβCD phức R-HPβCD 81 Bảng 3.34 Độ tan rutin dung dịch HBβCD nồng độ từ - 10 mmol 83 screening tool for estimating the potential of 2-hydroxypropyl-β-cyclodextrin complexation for solubilization purposes”, International Journal of Pharmaceutics 295, pp.163-175 12 Aiju Chen, Min Liu, Lina Dong, Dezhi Sun (2013), “Study on the effect of solvent on the inclusion interaction of hydroxypropyl-β-cyclodextrin with three kinds of coumarins by phase solubility method”, Fluid Phase Equilibria 341, pp.4247 13 Aiman A Obaidat, Rasha A Khanfar, Mohammad N Khawam (2009), “The effect of β-cyclodextrin on the solubility and dissolution rate of meloxicam and investigation of the driving force for complexation using molecular modeling”, J Incl Phenom Macrocycl Chem 63, pp.273-279 14 Amber Vyas, Shailendra Saraf, Swarnlata Saraf (2008), “Cyclodextrin based novel drug delivery systems”, J Incl Phenom Macrocycl Chem 62, pp.23-42 15 Anna Shevchenko, Luis M Bimbo, Inna Miroshnyk, Jorma Haarala, Kristýna Jelínková, Kaisa Syrjänen, Bert van Veen, Juha Kiesvaara, Hélder A Santos, Jouko Yliruusi (2012), “A new cocrystal and salts of itraconazole: Comparison of solid-state properties, stability and dissolution behavior”, International Journal of Pharmaceutics 436, pp.403-409 16 Arti Maheshwari, Manisha Sharma, Deepak Sharma (2012), “Complexation of sodium picosulphate with beta cyclodextrin: NMR spectroscopic study in solution”, J Incl Phenom Macrocycl Chem, Original article, pp.1-6 17 Ashok Katdare, Mahesh V Chaubal (2006), Excipient Developmentfor Pharmaceutical, Biotechnology, and Drug Delivery Systems, Informa Healthcare USA, Inc.Taylor & Francis Group, LLC, pp.15-17, 51-59, 93-97 18 Ashwini Madgulkar, Shivajirao Kadam, and Varsha Pokharkar (2008), “Studies on Formulation Development of Mucoadhesive Sustained Release Itraconazole Tablet Using Response Surface Methodology”, AAPS Pharm Sci Tech (3), pp.998-1005 19 Audur Magnusdottir, Mármásson and Thorsteinn Loftsson (2002), “Self Association and Cyclodextrin Solubilization of NSAIDs”, Journal of Inclusion Phenomena and Macrocyclic Chemistry 44, pp.213–218 20 Bengt Lindberg, Johan Lindberg, Josef Pitha, C Trinadha Rao, and Kazuaki Harata (1991), “Synthesis of some 2-0-(2-hydroxyalkyl) and 2-O-(2,3- dihydroxyalkyl) derivatives of cyclomaltoheptaose”, Carbohydrate Research 222, pp.113-119 21 British pharmacopoeia (2010), pp 252-254, 1075-1077, 1168-1170, 1357-1358, 1863-1864 22 Buchi N Nalluri, K.P.R Chowdary, K.V.R Murthy, V Satyanarayana, A.R Hayman and G Becket (2005), “Inclusion Complexation and Dissolution Properties of Nimesulide and Meloxicam-hydroxypropyl-β-cyclodextrin Binary Systems”, Journal of Inclusion Phenomena and Macrocyclic Chemistry 53, pp.103-110 23 C Trinadha Rao and Josef Pitha (1991), “Reactivities at the O-2, 0-3, and O-6 positions of cycloamyloses in Hakomori methylation”, Carbohydrate Research 220, pp.209-213 24 C Trinadha Rao, Josef Pitha, Bengt Lindberg, and Johan Lindberg (1992), “Distribution of substituents cyclomalto-oligosaccharides in O-(2-hydroxypropyl) (cyclodextrins): influence derivatives of of increasing substitution, of the base used in the preparation, and of macrocyclic size”, Carbohydrate Research 223, pp.99-107 25 Chao Yuan, Benguo Liu, Chungang Chen (2010), “Optimization of Preparation Process of Hydroxypropyl-β-Cyclodextrin by Response Surface Methodology”, International Conference on Challenges in Environmental Science and Computer Engineering, pp.26-28 26 Chao Yuan, Lei Du, Zhengyu Jin, Xueming Xu (2013), “Storage stability and antioxidant activity of complex of astaxanthin with hydroxypropyl-βcyclodextrin”, Carbohydrate Polymers 91, pp.385-389 27 Chao Yuan, Zhengyu Jin, Xuehong Li (2008), “Evaluation of complex forming ability of hydroxypropyl-β-cyclodextrins”, Food Chemistry 106, pp 50-55 28 Chao Yuan, Zhengyu Jin, Xueming Xu (2012), “Inclusion complex of astaxanthin with hydroxypropyl-β-cyclodextrin: UV, FTIR, 1H NMR and molecular modeling studies”, Carbohydrate Polymers 89, pp.492- 496 29 Chin Weng Yong, Clive Washington and William Smith (2008), “Structural Behaviour of 2-Hydroxypropyl-β-Cyclodextrin in Water: Molecular Dynamics Simulation Studies”, Pharmaceutical Research 25 (5), pp.1092-1099 30 Claudia Garnero, Ariana Zoppi, Diego Genovese, Marcela Longhi (2010), “Studies on trimethoprim: hydroxypropyl-β-cyclodextrin: aggregate and complex formation”, Carbohydrate Research 345, pp.2550-2556 31 Dan He, Ping Deng, Lin Yang, Qunyou Tan, Juan Liu, Mei Yang, Jingqing Zhang (2013), “Molecular encapsulation of rifampicin as an inclusion complex of hydroxypropyl-β-cyclodextrin: Design; characterization and in vitro dissolution”, Colloids and Surfaces B: Biointerfaces 103, pp.580-585 32 Ding Haiyun, Chao Jianbin, Zhang Guomei, Shuang Shaomin, Pan Jinhao (2003), “Preparation and spectral investigation on inclusion complex of β-cyclodextrin with rutin”, Spectrochimica Acta Part A 59, pp.3421-3429 13 33 E Inkmann, U Holzgrabe (1999), “ H and C nuclear magnetic resonance studies of the sites of protonation in itraconazole and fluconazole”, Journal of Pharmaceutical and Biomedical Analysis 20, pp.297-307 34 Ece Dilber Gamsiz, Avinash G Thombre, Imram Ahmed, and Rebecca Lyn Carrier (2011), “Drug Salts and Solubilization: Modeling the Influence of Cyclodextrins on Oral Absorption”, Annals of Biomedical Engineering 39 (1), pp.455-468 35 European pharmacopoeia 6.0 (2007), pp.1291-1292, 2194-2196, 2844-2845, 37633765 36 Francisco B T Pessine, Adriana Calderini and Guilherme L Alexandrino (2012), “Review: Cyclodextrin Inclusion Complexes Probed by NMR Techniques”, Intech Europe, pp.237-264 37 Gabriel Cendejas, César Andrés Flores-Sandoval, Nelson Huitrón, Rafael Herrera, Luis S Zamudio-Rivera, Hiram I Beltrán, Flavio Vázquez (2008), “Theoretical and experimental studies of the initiator influence on the anionic ring opening polymerization of propylene oxide”, Journal of Molecular Structure 879, pp.40-52 38 H O Ammar, M Ghorab, D M Mostafa, T S Makram, R M Ali (2012), “Host-guest system of etodolac in native and modified β-cyclodextrins: preparation and physicochemical characterization”, J Incl Phenom Macrocycl Chem, pp.1-14 39 H Trommer R.H.H Neubert (2006), “Overcoming the Stratum Corneum: The Modulation of Skin Penetration”, Skin Pharmacol Physiol 19, pp 106-121 40 Hakon H Sigurdsson, Audur Magnusdottir, Mármásson and Thorsteinn Loftsson (2002), “The Effects of Cyclodextrins on Hydrocortisone Permeability Through Semi-Permeable Membranes”, Journal of Inclusion Phenomena and Macrocyclic Chemistry 44, pp.163-167 41 Hazem A Hassan, Ali H Al-Marzouqi, Baboucarr Jobe, Alaa A Hamza, Gaber A Ramadan (2007), “Enhancement of dissolution amount and in vivo bioavailability of itraconazole by complexation with β-cyclodextrin using supercritical carbon dioxide”, Journal of Pharmaceutical and Biomedical Analysis 45, pp.243-250 42 Hiroshi Kakiuchi and Takao Lijima (1979), “The ring-opening reactions of propylene oxide with chloroacetic acids”, MnkdnmVd 36, pp.1011-1016 43 Hong Yuan Sun, Yan Bai, Ming Gang Zhao, Ai You Hao, Gui Ying Xu, Jian Shen, Jian Ye Li, Tao Sun, Hua Cheng Zhang (2009), “New cyclodextrin derivative 6-O-(2-hydroxybutyl)-β-cyclodextrin: preparation and its application in molecular binding and recognition”, Carbohydrate Research 344, pp.19992004 44 Huahua Wu, Hao Liang, Qipeng Yuan, Tianxin Wang, Xu Yan (2010), “Preparation and stability investigation of the inclusion complex of sulforaphane with hydroxypropyl-β-cyclodextrin”, Carbohydrate Polymers 82, pp.613-617 45 Ibrahim A Alsarra, Fars K Alanazi, Sayed M Ahmed, Ahmed A Bosela, Suliman S Alhamed, Hammam A Mowafy, and Steven H Neau (2010), “Comparative Study of Itraconazole-Cyclodextrin Inclusion Complexand Its Commercial Product”, Arch Pharm Res 33 (7), pp.1009-1017 46 Jacques Reuben, C Trinadha Rao, Joseph Pitha (1994), “Distribution of substituents in carboxymethyl ethers of cyclomaltoheptaose”, Carbohydrate Research 258, pp.281-285 47 Jessica Cano, Alberto Rodriguez, Emilio Aicart, Elena Junquera (2007), “Temperature effect on the complex formation between tricyclic antide pressant drugs (amitriptyline or imipramine) and hydroxypropyl-β- cyclodextrin in water”, J Incl Phenom Macrocycl Chem 59, pp.279-285 48 Jindrich Jindrich, Josef Pitha, Bengt Lindberg, Pia Seffers, Kazuaki Harata (1995), “Regioselectivity of alkylation of cyclomaltoheptaose (β-cyclodextrin) and synthesis of its mono-2-Omethyl, -ethyl,-allyl, and-propyl derivatives”, Carbohydrate Research 266, pp.75-80 49 Josef Pitha, C Trinadha Rao, Bengt Lindberg, and Pia Seffers (1990), “Distribution of substituents in 2-hydroxypropyl ethers of cyclomaltoheptaose”, Carbohydrate Research 200, pp.429-435 50 Josef Pitha, Jan Milecki, Henry Fales, Lewis Pannell and Kaneto Uerkama (1986), “Hydroxypropyl-β-cyclodextrin: preparation and characterization; effects on solubility of drugs”, International jounal of pharmaceutics 29, pp.73-82 51 Josef Pitha, Lajos Szabo, and Henry M.Fales (1987), “Reaction of cyclodextrins with propylene oxide or with glycidol: Analysis of product distribution”, Carbohydrate Research 168, pp.191-198 52 Jui-Sheng Chang, Yaw-Bin Huang, Sen-Sen Hou,Ren-Jiunn Wang, Pao-Chu Wu, Yi-Hung (2007), “Formulation optimization of meloxicam sodium gelusing response surface methodology”, International Journal of Pharmaceutics 338, pp.48-54 53 K Miyake, T Irie, H Arima, F Hirayama, K Uekama, M Hirano, Y Okamoto (1999), “Characterization of itraconazole: 2-hydroxypropyl-β-cyclodextrin inclusion complex in aqueous propylene glycol solution”, International Journal of Pharmaceutics 179, pp.237-245 54 Kazuaki Harata, C Trinadha Rao, Josef Pitha, Kazuhiro Fukunaga, and Kaneto Uekama (1991), “Crystal structure of 2-O-[(S)-2-hydroxypropyl] cyclomaltoheptaose”, Carbohydrate Research 222, pp 37-45 55 Krista A Keller, DVM (2011), “Therapeutic Review Itraconazole”, Journal of Exotic Pet Medicine 20 (2), pp.156-160 56 Krzysztof Cal, Katarzyna Centkowska (2008), “Use of cyclodextrins in topical formulations: Practical aspects”, European Journal of Pharmaceutics and Biopharmaceutics 68, pp.467-478 57 Lajos Szente, Jo´zsef Szejtli (1999), “Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development”, Advanced Drug Delivery Reviews 36, pp.17-28 58 Li-Juan Yang, Wen Chen, Shui-Xian Ma, Yun-Tao Gao, Rong Huang, Sheng-Jiao Yana, Jun Lin (2011), “Host-guest system of taxifolin and native cyclodextrin or its derivative: Preparation, characterization, inclusion mode, and solubilization”, Carbohydrate Polymers 85, pp.629-637 59 Lina Dong, Min Liu, Aiju Chen, Yong Wang, Dezhi Sun (2013), “Solubilities of quercetin in three β‐cyclodextrin derivative solutions at different temperatures”, Journal of Molecular Liquids 177, pp.204-208 60 M Adolfina Ruiz Martinez, Julián López-Viota Gallardo, María Mũnoz de Benavides, Juan de Dios García L´opez-Duran, Visitación Gallardo Lara (2007), “Rheological behavior of gels and meloxicam release”, International Journal of Pharmaceutics 333, pp.17-23 61 M.L Calabrò, S Tommasini, P Donato, R Stancanelli, D Raneri, S Catania, C Costa, V Villari, P Ficarra, R Ficarra (2005), “The rutin/β-cyclodextrin interactions in fully aqueous solution: spectroscopic studies and biological assays”, Journal of Pharmaceutical and Biomedical Analysis 36, pp.10191027 62 M.N Timofeeva, V.N Panchenko, Jong Won Jun, Zubair Hasan, O.V Kikhtyanin, I.P Prosvirin, Sung Hwa Jhung (2013), “Effect of the acid-base properties of metal phosphate molecular sieves on the catalytic performances in synthesis of propylene glycol methyl ether from methanol and propylene oxide”, Microporous and Mesoporous Materials 165, pp.84-91 63 Marcus E Brewster, Peter Neeskens, Jef Peeters (2007), “Solubilization of itraconazole as a function of cyclodextrin structural space”, J Incl Phenom Macrocycl Chem 57, pp.561-566 64 Marcus E Brewster, Roger Vandecruys, Jef Peeters, Peter Neeskens, Geert Verreck, Thorsteinn Loftsson (2008), “Comparative interaction of 2-hydroxypropyl-βcyclodextrin and sulfobutylether-β-cyclodextrin with itraconazole: Phasesolubility behavior and stabilization of supersaturated drug solutions”, European journal of pharmaceutical sciences 34, pp.94-103 65 Marcus E Brewster, Thorsteinn Loftsson (2007), “Cyclodextrins as pharmaceutical solubilizers”, Advanced Drug Delivery Reviews 59, pp.645-666 66 María José González-Álvarez, Antonio Di Marino, Francisco Mendicuti (2009), “Fluorescence, Induced Circular Dichroism and Molecular Mechanics of 1ethyl Naphthalenecarboxylate Complexes with 2-Hydroxypropyl Cyclodextrins”, J Fluoresc 19, pp.449-462 67 Mario Jug, Mira Bécirevíc-Lácan (2004), “Influence of hydroxypropyl-βcyclodextrin complexation on piroxicam release from buccoadhesive tablets”, European Journal of Pharmaceutical Sciences 21, pp.251-260 68 Martin Messner, Sergey V Kurkov, Marcus E Brewster, Phatsawee Jansook, Thorsteinn Loftsson (2011), “Self-assembly of cyclodextrin complexes: Aggregation of hydrocortisone/cyclodextrin complexes”, International Journal of Pharmaceutics 407, pp.174-183 69 Martin Messner, Sergey V Kurkov, Marta Maraver Palazón, Berta Álvarez Fernández, Marcus E Brewster, Thorsteinn Loftsson (2011), “Self-assembly of cyclodextrin complexes: Effect of temperature, agitation and media composition on aggregation”, International Journal of Pharmaceutics 419, pp.322-328 70 Martin Messner, Sergey V Kurkov, Phatsawee Jansook, Thorsteinn Loftsson (2010), “Self-assembled cyclodextrin aggregates and nanoparticles”, International Journal of Pharmaceutics 387, pp.199-208 71 Martin Messner, Sergey V Kurkov, Ramon Flavià-Piera, Marcus E Brewster, Thorsteinn Loftsson (2011), “Self-assembly of cyclodextrins: The effect of the guest molecule”, International Journal of Pharmaceutics 408, pp.235-247 72 Mauro Banchero, Luigi Manna (2011), “Investigation of the piroxicam/hydroxypropyl-β-cyclodextrin inclusion complexation by means of a supercritical solvent in the presence of auxiliary agents”, J of Supercritical Fluids 57, pp.259-266 73 Ming-gang Zhao, Ai-you Hao, Jian Li, Yun-he Wei and Peng Guo (2005), “New cyclomaltoheptaose (β-cyclodextrin) derivative 2-O-(2-hydroxybutyl) cyclomaltoheptaose: preparation and its application for the separation of enantiomers of drugs by capillary electrophoresis”, Carbohydrate Research 340, pp.1563-1565 74 Narcisa Marangoci, Mihai Mares, Mihaela Silion, Adrian Fifere, Cristian Varganici, Alina Nicolescu, Calin Deleanu, Adina Coroaba, Mariana Pinteala, Bogdan C Simionescu (2011), “Inclusion complex of a new propiconazole derivative with β-cyclodextrin: NMR, ESI-Ms and preliminary pharmacological studies”, Results in PharmaSciences 1, pp.27-37 75 Peter Lu ger, Klaus Daneck, Wolfhard Engel, Giinter Trummhtz, Klaus Wagner (1996), “Structure and physicochemical properties of meloxicam, a new nsaid”, European Journal of Pharmaceutical Sciences 4, pp.175-187 76 R Ficarra, P Ficarra, M.R Di Bella, D Raneri, S Tommasini, M.L Calabrò, M.C Gamberini, C Rustichelli (2000), “Study of β-blockers: β-cyclodextrins inclusion complex by NMR, DSC, X-ray and SEM investigation”, Journal of Pharmaceutical and Biomedical Analysis 23, pp.33-40 77 R Jantharaprapap, G Stagni (2007), “Effects of penetration enhancers on in vitro permeability of meloxicam gels”, International Journal of Pharmaceutics 343, pp.26-33 78 Rajeswari Challa, Alka Ahuja, Javed Ali, and R.K Khar (2005), “Cyclodextrins in Drug Delivery: An Updated Review”, AAPS Pharm SciTech (2), E 329- E 357 79 Rebecca L Carrier, Lee A Miller, Imran Ahmed (2007), “The utility of cyclodextrins for enhancing oral bioavailability”, Journal of Controlled Release 123, pp.78-99 80 Renu Chadha, Sushma Gupta, Geeta Shukla, D.V.S.Jain, Raghuvir R.S Pissurlenkar, Evans C.Coutinho (2011), “Interaction of artesunate with βcyclodextrin: Characterization, thermodynamic parameters, molecular modeling, effect of PEG on complexation and antimalarial activity”, Results in PharmaSciences 1, pp.38-48 81 Romina J Glisoni & Diego A Chiappetta & Albertina G Moglioni & Alejandro Sosnik (2012), “Novel 1-indanone Thiosemicarbazone Antiviral Candidates: Aqueous Solubilization and Physical Stabilization by Means of Cyclodextrins”, Pharm Res 29, pp.739-755 82 S Baboota and S.P Agarwal (2005), “Preparation and Characterisation of Meloxicam Hydroxy Propyl β-Cyclodextrin Inclusion Complex”, Journal of Inclusion Phenomena and Macrocyclic Chemistry 51, pp.219-224 83 Sang-Yun Lee, In-Il Jung, Jeong-Kyu Kim, Gio-Bin Lim, Jong-Hoon Ryu (2008), “Preparation of itraconazole/HP-β-CD inclusion complexes using supercritical aerosol solvent extraction system and their dissolution characteristics”, J of Supercritical Fluids 44, pp.400-408 84 Sarah Gould, Robert C Scott (2005), “2-Hydroxypropyl-β-cyclodextrin (HP-β-CD): A toxicology review”, Food and Chemical Toxicology 43, pp 1451-1459 85 Sergey V Kurkov, Elena V Ukhatskaya, Thorsteinn Loftsson (2011), “Drug/cyclodextrin: beyond inclusion complexation”, J Incl Phenom Macrocycl Chem 69, pp.297-301 86 Sergey V Kurkov, Thorsteinn Loftsson (2013), “Review Cyclodextrins”, International Journal of Pharmaceutics 453, pp.167-180 87 Seung Hei Cho, SoYeon Kim, Sang In Lee, and Young Moo Lee (2006), “Hydroxypropyl-β-cyclodextrin inclusion complexes for transdermal delivery: preparation, inclusion properties, stability, and release behavior”, J Ind Eng Chem 12 (1), pp.50-59 88 Songsong An, Jiang He, Lijuan Sun, Dong Ren, Yihe Ban (2013), “Investigation of the inclusion behavior of HP-β-cyclodextrin with polydatinin solution and its analytical application”, Journal of Molecular Structure 1037, pp.9-14 89 Sonia Pandey, Brijesh kumar, S.M Vijayendra Swamy, Arti Gupta (2010), “A review on pharmaceutical application of cyclodextrins”, International Journal Of Pharmacy & Technology, IJPT (3), pp.281-319 90 Takako Ishiguro, Eri Morishita, Daisuke Iohara, Fumitoshi Hirayama, Koki Wada, Keiichi Motoyama, Hidetoshi Arima, Kaneto Uekama (2011), “Some pharmaceutical and inclusion properties of 2-hydroxybutyl-β-cyclodextrin derivative”, International Journal of Pharmaceutics 419, pp.161-169 91 Takako Ishiguro, Fumitoshi Hirayama, Daisuke Iohara, Hidetoshi Arima, Kaneto Uekama (2010), chlorpropamide “Crystallization in aqueous and polymorphic transitions 2-hydroxybutyl-β-cyclodextrin European Journal of Pharmaceutical Sciences 39, pp.248-255 of solution”, 92 Tao Tao, Yan Zhao, JinjinWu, Beiyi Zhou (2009), “Preparation and evaluation of itraconazole dihydrochloride for the solubility and dissolution rate enhancement”, International Journal of Pharmaceutics 367, pp.109-114 93 Thierry Van Hees, Geraldine Piel, Sandrine Henry de Hassonville, Brigitte Evrard, Luc Delattre (2002), “Determination of the free/included piroxicam ratio in cyclodextrin complexes: comparison between UV spectrophotometry and differential scanning calorimetry”, European Journal of Pharmaceutical Sciences 15, pp.347-353 94 Thomas Taupitz, Jennifer B Dressman, Charles M Buchanan, Sandra Klein (2013), “Cyclodextrin-water soluble polymer ternary complexes enhance the solubility and dissolution behaviour of poorly soluble drugs Case example: Itraconazole”, European Journal of Pharmaceutics and Biopharmaceutics 83, pp.378-387 95 Thorsteinn Loftsson, Dagný Hreinsdóttir, Már Másson (2005), “Evaluation of cyclodextrin solubilization of drugs”, International Journal of Pharmaceutics 302, pp.18-28 96 Thorsteinn Loftsson, Dagný Hreinsdó ttir, Már Másson (2007), “The complexation efficiency”, J Incl Phenom Macrocycl Chem 57, pp 545-552 97 Thorsteinn Loftsson, Már Másson, Hákon H Sigurdsson (2002), “Cyclodextrins and drug permeability through semi-permeable cellophane membranes”, International Journal of Pharmaceutics 232, pp.35-43 98 Tien An Nguyen, Benguo Liu, Jian Zhao, Donald S Thomas, James M Hook (2013), “An investigation into the supramolecular structure, solubility, stability and antioxidant activity of rutin/cyclodextrin inclusion complex”, Food Chemistry 136, pp.186-192 99 USP 35-NF 30 (2012), pp.1715-1716, 1819-1821, 3604-3605, 3789-3794 100 V Kestens, R Zeleny, G Auclair, A Held, G Roebben, T.P.J Linsinger (2011), “Differential scanning calorimetry method for purity determination: A case study on polycyclic aromatic hydrocarbons and chloramphenicol”, Thermochimica Acta 524, pp.1-6 101 Valentino J Stella, Venkatramana M Rao, Erika A Zannou, Vahid Zia (1999), “Mechanisms of drug release from cyclodextrin complexes”, Advanced Drug Delivery Reviews 36, pp.3-16 102 Varun Raj Vemula, Venkateshwarlu Lagishetty, Srikanth Lingala (2010), “Solubility enhancement techniques”, International Journal of Pharmaceutical Sciences Review and Research (1), pp.41-51 103 Vikas A Saharan, Vipin Kukkar, Mahesh Kataria, Manoj Gera, Pratim K Choudhury (2009), “Dissolution Enhancement of Drugs Part I: Technologies and Effect of Carriers”, Review Article International Journal of Health Research 2, pp.107124 104 Vikas A Saharan, Vipin Kukkar, Mahesh Kataria, Manoj Gera, Pratim K Choudhury (2009), “Dissolution Enhancement of Drugs Part II: Effect of Carriers”, Review Article, International Journal of Health Research 2, pp.207-223 105 W Zielenkiewicz, I.V Terekhova, M Koz´bial, R.S Kumeev (2010), “Thermodynamic study on inclusion complex formation of riboflavin with hydroxypropyl-β-cyclodextrin in water”, J Therm Anal Calorim 101, pp.595600 106 W.J Sichina (2000), “Purity Measurements of Pharmaceuticals and Organics by DSC”, Thermal Analysis, pp.1-4 107 Walter Snor, Elisabeth Liedl, Petra Weiss-Greiler, Helmut Viernstein, Peter Wolschann (2009), “Density functional calculations on meloxicam-βcyclodextrin inclusion Complexes”, International Journal of Pharmaceutics 381, pp.146-152 108 Wei Yang, Keat Theng Chow, Bo Lang, Nathan P Wiederhold, Keith P Johnston, Robert O Williams III (2010), “In vitro characterization and pharmacokinetics in mice following pulmonary delivery of itraconazole as cyclodextrin solubilized solution”, European Journal of Pharmaceutical Sciences 39, pp.336-347 109 Wieslawa Misiuk, Magdalena Zalewska (2009), “Investigation of inclusion complex of trazodone hydrochloride with hydroxypropyl-β-cyclodextrin”, Carbohydrate Polymers 77, pp.482-488 110 Wieslawa Misiuk, Magdalena Zalewska (2011), “Spectroscopic investigations on the inclusion interaction between hydroxypropyl-β-cyclodextrin and bupropion”, Journal of Molecular Liquids 159, pp.220-225 111 Xiuli Lin, Chenfu Zhu, Aiyou Hao (2005), “Enantioseparation in capillary electrophoresis using 2-O-(2-hydroxybutyl)-β-CD as a chiral selector”, Electrophoresis 26, pp.3890-3896 112 Xuemin Yang, Yulin Zhao, Yunjian Chen, Xiali Liao, Chuanzhu Gao, Dan Xiao, Qixue Qin, Dong Yi, Bo Yang (2013), “Host-guest inclusion system of mangiferin with β-cyclodextrin and its derivatives”, Materials Science and Engineering C 33, pp.2386-2391 113 YA Khlebitskii, M.G.Makarov and V.F.Shvets (1975), “Study of relations governing the distribution of composition of reaction products of propylene oxide with alcohols”, Vysokomol soyed A17 (10), pp 2320-2324 114 Yifeng He, Pei Fu, Xinghai Shen, Hongcheng Gao (2008), “Cyclodextrin-based aggregates and characterization by microscopy”, Micron 39, pp.495-516 115 Yoichi Ikeda, Kenya Kimura, Fumitoshi Hirayama, Hidetoshi Arima,Kaneto Uekama (2000), “Controlled release of a water-soluble drug, captopril, by acombination of hydrophilic and hydrophobic cyclodextrin derivatives”, Journal of Controlled Release 66, pp.271-280 116 Zhouhua Wang, Zixin He, Lei Zhang, Haohao Zhang, Meimei Zhang, Xinguo Wen, Guilan Quan, Xintian Huang, Xin Pan, Chuanbin Wu (2013), “Optimization of a doxycycline hydroxypropyl-β-cyclodextrin inclusion complex base don computational modeling”, Acta Pharmaceutica Sinica B (2), pp.130-139 117 Zita Sebestyén, Ágnes Buvári-Barcza, János Rohonczy (2012), “pH-dependent complex formation of amino acids with β-cyclodextrin and quaternary ammonium β-cyclodextrin”, J Incl Phenom Macrocycl Chem 73, pp.199-210 PHỤ LỤC ... nghiệm thuốc khác hồn tồn với 2-hydroxybutyl -β- cyclodextrin dùng làm tá dƯợc áp dụng qui trình vào tổng hợp HBβCD dùng làm tá dƯợc đƯợc Nghiên cứu tổng hợp ứng dụng 2-hydroxybutyl -β- cyclodextrin bào. .. hydroxyalkyl- β- cyclodextrin ứng dụng làm tá dƯợc tăng độ tan bào chế thuốc? ?? đƯợc thực gồm mục tiêu cụ thể sau: Tổng hợp 2-hydroxypropyl -β- cyclodextrin 2-hydroxybutyl -β- cyclodextrin: 1.1 Xây dựng qui trình tổng hợp HPβCD... 2-hydroxybutyl -β- cyclodextrin tổng hợp vào tạo phức với số dƯợc chất tan: 2.1 Điều chế phức rutin-hydroxypropyl -β- cyclodextrin (R-HPβCD), phức rutinhydroxybutyl -β- cyclodextrin (R-HBβCD) 2.2 So sánh độ hòa tan, độ tan